<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25242447</article-id>
      <article-id pub-id-type="pmc">4247719</article-id>
      <article-id pub-id-type="publisher-id">1821</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-12-293</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary Ewing sarcoma/primitive neuroectodermal tumor of the renal pelvis: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Zhihong</given-names>
          </name>
          <address>
            <email>zhihong031@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff24"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Xianding</given-names>
          </name>
          <address>
            <email>urowang@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff24"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>You</given-names>
          </name>
          <address>
            <email>lauraluyou@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff25"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Libo</given-names>
          </name>
          <address>
            <email>610502795@qq.com</email>
          </address>
          <xref ref-type="aff" rid="Aff24"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lu</surname>
            <given-names>Yiping</given-names>
          </name>
          <address>
            <email>yipinglu@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff24"/>
        </contrib>
        <aff id="Aff24"><label/>Department of Urology, West China Hospital, Sichuan University, Number 37, Guoxue Alley, Chengdu, Sichuan, 610041 The People&#x2019;s Republic of China </aff>
        <aff id="Aff25"><label/>Department of paediatrics, West China Second University Hospital, Chengdu, Sichuan Province 610041 China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>22</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>12</volume>
      <elocation-id>293</elocation-id>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>9</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>4</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Liu et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is a childhood malignancy, typically occurring in the bone and rarely in any other part of the body. We herein present a case of ES/PNET of the renal pelvis. A 37-year-old male patient presented with a chief complaint of pain in the left flank and gross hematuria. The tumor had caused moderate hydronephrosis, and ureteroscopic biopsy findings were highly suspicious of sarcoma. Subsequently, radical nephroureterectomy was performed. On the basis of the pathological and cytogenetic findings, a final diagnosis of primary ES/PNET of left renal pelvis was made. Adjuvant chemotherapy with adriamycin and ifosfamide was initiated as ES/PNET often exhibits aggressive biological behavior. The patient was disease-free at his last regular follow-up visit 18&#xA0;months after the surgery. To our knowledge, this is the first reported case of primary ES/PNET of the renal pelvis.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Ewing sarcoma</kwd>
        <kwd>Diagnosis</kwd>
        <kwd>Primitive neuroectodermal tumor</kwd>
        <kwd>Renal pelvis</kwd>
        <kwd>Therapeutics</kwd>
        <kwd>Ureteroscopic biopsy</kwd>
        <kwd>Nephroureterectomy</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is the second most common form of bone malignancy (after osteosarcoma) occurring in childhood [<xref ref-type="bibr" rid="CR1">1</xref>]. However, ES/PNET of extra-skeletal origin is an extremely rare entity. With the exception of ES/PNET arising from the renal parenchyma, ES/PNET of the renal pelvis has never been reported in the literature. To help establish the biological nature of primary ES/PNET of the renal pelvis, we present the clinical, diagnostic, and therapeutic aspects of this rare neoplasm along with a review of the literature.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 37-year-old male patient was admitted with a chief complaint of intermittent pain in the left plank and gross hematuria. His past medical history and findings of a physical examination were unremarkable. Results of his blood chemistry and routine blood tests were within the normal range. Urine cytology showed no signs of malignancy. Ultrasonography demonstrated a 4-cm hypoechoic mass occupying the dilated left renal pelvis, the presence of which was subsequently confirmed by enhanced computed tomography (CT) (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) and left retrograde pyelography. Cytology of the washout fluid obtained from the retrograde catheterization was also negative for malignancy. Further clinical investigations showed no evidence of metastasis. A preoperative ureteroscopic biopsy performed, with findings highly suspicious of sarcoma. The patient subsequently underwent open, left radical nephroureterectomy with excision of the bladder cuff. No intraoperative or postoperative complications developed.</p>
      <p>Macroscopic examination showed that a 4.0&#x2009;&#xD7;&#x2009;2.3&#x2009;&#xD7;&#x2009;1.5&#xA0;cm soft tissue mass was situated in the renal pelvis, with lobulated contours, a gray-white cut surface, and an intact renal parenchyma. Microscopic examination revealed a small round cell tumor with focal necrosis, infiltrating the smooth muscle layer of the renal pelvis and without renal parenchyma involvement. On immunohistochemistry, the tumor cells stained positive for CD99 (Figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>), CD56, S-100, and vimentin; focally positive for epithelial membrane antigen and Ki-67; and negative for Bcl-2, cytokeratin 7, cytokeratin 20, desmin, WT-1, muscle specific actin, and Syn. On the basis of these findings, a pathological diagnosis of primary ES/PNET of the left renal pelvis was made. The diagnosis was further confirmed by fluorescence in situ hybridization (FISH) to detect the presence of EWS/FLI-1 fusion products. Adjuvant chemotherapy with adriamycin and ifosfamide was administered as ES/PNET often exhibit highly aggressive biological behavior. The patient was in excellent physical and mental condition without recurrence or metastasis as confirmed by careful follow-up at 18&#xA0;months postoperatively.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Contrast-enhanced CT demonstrating a 4-cm soft-tissue mass occupying the dilated left renal pelvis. (A)</bold> Enhanced CT. <bold>(B)</bold> Left retrograde pyelography.</p></caption><graphic xlink:href="12957_2013_1821_Fig1_HTML" id="d30e255"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Immunohistochemistry showed intense positive membranous CD99 staining.</bold>
</p></caption><graphic xlink:href="12957_2013_1821_Fig2_HTML" id="d30e267"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="conclusions">
      <title>Conclusion</title>
      <p>During the past two decades, nine cases of primary sarcoma of the renal pelvis have been described in the English literature: six of leiomyosarcoma, two of rhabdomyosarcoma, and one of cystic embryonal sarcoma (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR10">10</xref>]. To our knowledge, this is the first case of primary ES/PNET of the renal pelvis to be reported in the literature. Although being a rare entity, sarcoma should be included in the preoperative differential diagnosis of renal pelvis tumors. However, preoperative diagnosis of sarcoma is often difficult because of its rare incidence, non-specific clinical presentation, and radiological features (similar to those of urothelial carcinoma). Tsai et al. [<xref ref-type="bibr" rid="CR8">8</xref>] and Chow et al. [<xref ref-type="bibr" rid="CR9">9</xref>] reported the use of fine-needle aspiration biopsy with good results for primary renal pelvis sarcoma. Furthermore, for tumors of the upper urinary tract, ureteroscopic biopsy may be useful in establishing a more accurate preoperative diagnosis and deciding on the surgical modality, as was performed in the case reported here.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Sarcoma of the renal pelvis reported in the English literature during the past two decades</bold>
[<xref ref-type="bibr" rid="CR2">2</xref>&#x2013;<xref ref-type="bibr" rid="CR10">10</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th>First author/Year</th><th>Age (yr)/Sex</th><th>Symptoms &amp; signs</th><th>Side</th><th>Size (cm)</th><th>Therapy</th><th>Histological subtype</th><th>Follow-up</th></tr></thead><tbody><tr><td>Chow 1994</td><td>56/F</td><td>Abdominal distension</td><td>R</td><td>15</td><td>RN, thromb-ectomy</td><td>Leiomyosarcoma</td><td>2&#xA0;yr/DOM</td></tr><tr><td>Ito 2000</td><td>12/M</td><td>Abdominal pain, massive bleeding</td><td>R</td><td>NA</td><td>SN</td><td>Cystic embryonal sarcoma</td><td>26&#xA0;yr/NED</td></tr><tr><td>Moudouni 2001</td><td>41/M</td><td>Flank pain, gross hematuria</td><td>L</td><td>2</td><td>RNU</td><td>Leiomyosarcoma</td><td>8&#xA0;yr/NED</td></tr><tr><td>Kren 2003</td><td>49/F</td><td>Flank pain</td><td>R</td><td>1.8</td><td>RNU</td><td>Rhabdomyo-sarcoma</td><td>2&#xA0;yr/NED</td></tr><tr><td>Minami 2004</td><td>54/M</td><td>Bowel discomfort</td><td>L</td><td>8</td><td>RN</td><td>Leiomyosarcoma</td><td>6 mo/NED</td></tr><tr><td>Kartsanis 2006</td><td>44/M</td><td>Gross hematuria</td><td>L</td><td>5</td><td>RNU, PL</td><td>Leiomyosarcoma</td><td>3&#xA0;yr/NED</td></tr><tr><td>Tsai 2006</td><td>77/F</td><td>Gross hematuria, voiding difficulty, flank tenderness</td><td>R</td><td>2</td><td>RN</td><td>Rhabdomyo-sarcoma</td><td>5 mo/Alive</td></tr><tr><td>Chung 2007</td><td>42/F</td><td>Asymptomatic</td><td>L</td><td>5</td><td>RN</td><td>Leiomyosarcoma</td><td>NA</td></tr><tr><td>Dhamne 2009</td><td>60/M</td><td>Urinary frequency, weakness, weight loss</td><td>R</td><td>10</td><td>RN</td><td>Leiomyosarcoma</td><td>6 mo/NED</td></tr><tr><td>Our case 2012</td><td>37/M</td><td>Flank pain, gross hematuria</td><td>L</td><td>4</td><td>RNU, chemo-therapy</td><td>Ewing&#x2019;s sarcoma</td><td>4&#xA0;yr/NED</td></tr></tbody></table></table-wrap></p>
      <p>Histologically, lymphoblastic lymphoma, neuroblastoma, rhabdomyosarcoma, poorly differentiated synovial sarcoma, and Wilms tumor are included in the differential diagnosis of ES/PNET because they are all small round cell tumors. High levels of universal membranous CD99 expression are seen in ES/PNET cells, but this is not specific for ES/PNET. Thus, a broad immunohistochemistry panel may aid in differentiating these unique entities, even though this is sometimes difficult. Recently, molecular techniques have been increasingly used to confirm the diagnosis of ES/PNET, as it is one of the few solid tumors for which underlying chromosomal translocations have been described [<xref ref-type="bibr" rid="CR11">11</xref>]. The most common translocation is the t(11, 22) (q24; q12), detected in more than 85% of ES/PNET by FISH or reverse transcription-polymerase chain reaction. Accurate diagnosis is essential, as these tumors require different treatment strategies.</p>
      <p>As ES/PNET rarely spreads to lymph nodes, the single most important factor considered when planning initial treatment is the extent of disease at presentation, with the lungs being the most common site of metastasis. Initial presentation is the main factor that influences prognosis. The 5-year survival rate associated with extraskeletal ES/PNET in adults is 60% and 33% for non-metastatic and metastatic disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], respectively. Surgical resection may be the treatment of choice for local control in ES/PNET. However, ES/PNET often results in rapid recurrence or metastasis, even after complete resection. Therefore, patients with ES/PNET may require multidisciplinary management, combining systemic neoadjuvant and/or adjuvant chemotherapy with local control measures (surgery and/or radiation). Ifosfamide-based protocols appear to confer a survival advantage in ES/PNET patients [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Novel molecular-targeted therapies for the treatment of ES/PNET have now transitioned from the laboratory to the clinical setting. In a recent phase I trial of a fully human IgG2 monoclonal antibody targeting the insulin-like growth-factor-1 receptor, figitumumab, a number of patients with refractory, advanced ES/PNET responded unexpectedly well [<xref ref-type="bibr" rid="CR14">14</xref>]. Such patients should be informed about relevant clinical trials and encouraged to enter these trials. Due to the rarity of this condition, the impact of different treatment modalities (simple nephrectomy <italic>vs.</italic> radical nephrectomy <italic>vs.</italic> radical nephroureterectomy with or without chemotherapy and/or radiotherapy) on outcomes cannot be evaluated until more cases have been reported.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>YL designed the research project. ZL, XW, YL, and LC prepared the manuscript and collected the documents. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <p>Due to a limit on the number of references, many primary papers could not be cited. We apologize for this.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Balamuth</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Womer</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
          <article-title>Ewing&#x2019;s sarcoma</article-title>
          <source>Lancet Oncol</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>184</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70286-4</pub-id>
          <pub-id pub-id-type="pmid">20152770</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhamne</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Gadgil</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Padmanabhan</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Leiomyosarcoma of the renal pelvis</article-title>
          <source>Indian J Pathol Microbiol</source>
          <year>2009</year>
          <volume>52</volume>
          <fpage>549</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="doi">10.4103/0377-4929.56161</pub-id>
          <pub-id pub-id-type="pmid">19805970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>YG</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Seong</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Leiomyosarcoma arising from the blind end of a bifid renal pelvis</article-title>
          <source>Yonsei Med J</source>
          <year>2007</year>
          <volume>48</volume>
          <fpage>557</fpage>
          <lpage>560</lpage>
          <pub-id pub-id-type="doi">10.3349/ymj.2007.48.3.557</pub-id>
          <pub-id pub-id-type="pmid">17594170</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kartsanis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Douros</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zolota</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Perimenis</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Case report: leiomyosarcoma of the renal pelvis</article-title>
          <source>Int Urol Nephrol</source>
          <year>2006</year>
          <volume>38</volume>
          <fpage>211</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="doi">10.1007/s11255-006-0019-0</pub-id>
          <pub-id pub-id-type="pmid">16868685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minami</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ueki</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hashimoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kawaguchi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Case of leiomyosarcoma of the renal pelvis</article-title>
          <source>Int J Urol</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>122</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-2042.2004.00747.x</pub-id>
          <pub-id pub-id-type="pmid">14706019</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moudouni</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>En-Nia</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rioux-Leclerq</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guille</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lobel</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Leiomyosarcoma of the renal pelvis</article-title>
          <source>Scand J Urol Nephrol</source>
          <year>2001</year>
          <volume>35</volume>
          <fpage>425</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="doi">10.1080/003655901753224530</pub-id>
          <pub-id pub-id-type="pmid">11771874</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ito</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Monobe</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sakamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Embryonal sarcoma of adult and pediatric kidneys: report of a case with localized submucosal invasion of the renal pelvis and long-term survival</article-title>
          <source>Pathol Int</source>
          <year>2000</year>
          <volume>50</volume>
          <fpage>832</fpage>
          <lpage>838</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1440-1827.2000.01113.x</pub-id>
          <pub-id pub-id-type="pmid">11107056</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>Botryoid-type pleomorphic rhabdomyosarcoma of the renal pelvis in an adult. A rare case report and review of the literature</article-title>
          <source>Urol Int</source>
          <year>2006</year>
          <volume>77</volume>
          <fpage>89</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1159/000092943</pub-id>
          <pub-id pub-id-type="pmid">16825824</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chow</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Fine needle aspiration cytodiagnosis of leiomyosarcoma of the renal pelvis. A case report with immunohistochemical study</article-title>
          <source>Acta Cytol</source>
          <year>1994</year>
          <volume>38</volume>
          <fpage>759</fpage>
          <lpage>763</lpage>
          <pub-id pub-id-type="pmid">8091913</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kren</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Goncharuk</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Votava</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hermanova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Nazeer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dvorak</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Botryoid-type of embryonal rhabdomyosarcoma of renal pelvis in an adult. A case report and review of the literature</article-title>
          <source>Cesk Patol</source>
          <year>2003</year>
          <volume>39</volume>
          <fpage>31</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">12673941</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delattre</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Zucman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Plougastel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Desmaze</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Melot</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kovar</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Joubert</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rouleau</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Aurias</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours</article-title>
          <source>Nature</source>
          <year>1992</year>
          <volume>359</volume>
          <fpage>162</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="doi">10.1038/359162a0</pub-id>
          <pub-id pub-id-type="pmid">1522903</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwamoto</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis and treatment of Ewing&#x2019;s sarcoma</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>2007</year>
          <volume>37</volume>
          <fpage>79</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1093/jjco/hyl142</pub-id>
          <pub-id pub-id-type="pmid">17272319</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grier</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Krailo</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Tarbell</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Link</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Fryer</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Pritchard</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Gebhardt</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Dickman</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Perlman</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Donaldson</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rausen</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Vietti</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Miser</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Addition of ifosfamide and etoposide to standard chemotherapy for Ewing&#x2019;s sarcoma and primitive neuroectodermal tumor of bone</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <fpage>694</fpage>
          <lpage>701</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa020890</pub-id>
          <pub-id pub-id-type="pmid">12594313</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olmos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Postel-Vinay</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Molife</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Okuno</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Schuetze</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Paccagnella</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Batzel</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pritchard-Jones</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Judson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Worden</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Gualberto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scurr</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>de Bono</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Haluska</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing&#x2019;s sarcoma: a phase 1 expansion cohort study</article-title>
          <source>Lancet Oncol</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>129</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70354-7</pub-id>
          <pub-id pub-id-type="pmid">20036194</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
